Survival rate among Thai systemic lupus erythematosus patients in the era of aggressive treatment

International Journal of Rheumatic Diseases

Volumn 14, Issue 4, 2011, Pages 353-360

  Foocharoen, Chingching ^a   Nanagara, Ratanavadee ^a   Suwannaroj, Siraphop ^a   Mahakkanukrauh, Ajanee ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Cause of death; Lupus; Mortality; Survival rate; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; STEROID;

ADULT; ARTICLE; CAUSE OF DEATH; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; ONSET AGE; OPPORTUNISTIC INFECTION; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THAILAND;

ADOLESCENT; ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THAILAND; YOUNG ADULT;

EID: 80054701894     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2011.01639.x     Document Type: Article

References (33)

1. Helve T (1985) Prevalence and mortality rates of systemic lupus erythematosus and causes of death in SLE patients in Finland. Scand J Rheumatol 14, 43-6.
2. Cervera R, Khamashta MA, Font J, et al. (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine (Baltimore) 82, 299-308.
3. Cervera R, Khamashta MA, Font J, et al. (1999) Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 78, 167-75.
4. Mok CC, Mak A, Chu WP, To CH, Wong SN (2005) Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Medicine (Baltimore) 84, 218-24.
5. Yeap SS, Chow SK, Manivasagar M, Veerapen K, Wang F (2001) Mortality patterns in Malaysian systemic lupus erythematosus patients. Med J Malaysia 56, 308-12.
6. Rodríguez VE, González-Parés EN (2000) Mortality study in Puerto Ricans with systemic lupus erythematosus. P R Health Sci J 19, 335-9.
7. Kim WU, Min JK, Lee SH, Park SH, Cho CS, Kim HY (1999) Causes of death in Korean patients with systemic lupus erythematosus: a single center retrospective study. Clin Exp Rheumatol 17, 539-45.
8. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J (1995) Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 22, 1259-64.
9. Jacobsen S, Petersen J, Ullman S, et al. (1999) Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheumatol 28, 75-80.
10. Paton NI, Cheong I, Kong NC, Segasothy M (1996) Mortality in Malaysians with systemic lupus erythematosus. Med J Malaysia 51, 437-41.
11. Mok CC, Lee KW, Ho CT, Lau CS, Wong RW (2000) A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 39, 399-406.
12. Kasitanon N, Louthrenoo W, Sukitawut W, Vichainun R (2002) Causes of death and prognostic factors in Thai patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 20, 85-91.
13. Blanco FJ, Gómez-Reino JJ, de la Mata J, et al. (1998) Survival analysis of 306 European Spanish patients with systemic lupus erythematosus. Lupus 7, 159-63.
14. Bellomio V, Spindler A, Lucero E, et al. (2000) Systemic lupus erythematosus: mortality and survival in Argentina. A multicenter study. Lupus 9, 377-81.
15. Cohen MG, Li EK (1992) Mortality in systemic lupus erythematosus: active disease is the most important factor. Aust NZ J Med 22, 5-8.
16. Ward MM, Pyun E, Studenski S (1996) Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 156, 1337-44.
17. Koh ET, Seow A, Leong KH, Chng HH (1997) SLE mortality in an oriental population. Lupus 6, 27-31.
18. Ward MM, Pyun E, Studenski S (1995) Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum 38, 1492-99.
19. Demina AB, Radenska-Lopovok SG, Folomeeva OM, Erdes S (2005) The causes of death of patients with rheumatic diseases in Moscow. Klin Med (Mosk) 83, 36-43 (Abstract).
20. Tan EM, Cohen AS, Fries JF, et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25, 1271-7.
21. Bernatsky S, Boivin J, Joseph L, et al. (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54, 2550-7.
22. Wadee S, Tikly M, Hopley M (2007) Causes and predictors of death in South Africans with systemic lupus erythematosus. Rheumatology (Oxford) 46, 1487-91.
23. Nanagara R, Nantiruj K, Laopaiboon M (1990) Clinical study of the outcome in systemic lupus erythematosus: cause of death and prognosis factors. Intern Med 6, 1-5.
24. Asanuma Y, Oeser A, Shintani AK, et al. (2003) Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349, 2407-15.
25. El-Magadmi M, Bodill H, Ahmad Y, et al. (2004) Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 110, 399-404.
26. Roman MJ, Shanker B, Davis A, et al. (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349, 2399-406.
27. Geerlings SE, Hoepelman AI (1999) Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 26, 259-65.
28. Kaiser R, Cleveland CM, Criswell LA (2009) Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 68, 238-41.
29. Borba EF, Bonfá E (2001) Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28, 780-5.
30. Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB (2000) Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 27, 2142-5.
31. Kamen DL (2009) How can we reduce the risk of serious infection for patients with systemic lupus erythematosus? Arthritis Res Ther 11, 129.
32. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. (2006) Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15, 577-83.
33. Shinjo SK, Bonfá E, Wojdyla D, et al. (2010) Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 62, 855-62.